EXETER, N.H.--(BUSINESS WIRE)--Bentley Pharmaceuticals, Inc. (NYSE: BNT), a specialty pharmaceutical company, announced that, following successful review of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration, a Phase II program is now in effect and under way evaluating Bentley’s human recombinant Intranasal Insulin Spray for the treatment of postprandial hyperglycemia in diabetics.
